Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 9/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | AR | P10275 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18099888 | 1.00 | TSHR (0.43) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL5936332 | 1.00 | TSHR (0.43) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL17882107 | 0.83 | MAOB (0.42) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL17860841 | 0.83 | MAPT (0.46) | MAOBALDH1A1 | |
| SCHEMBL8139136 | 0.81 | MAOB (0.43) | MAOB | |
| SCHEMBL9010788 | 0.80 | MAOB (0.44) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL13039624 | 0.80 | TSHR (0.46) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL12679302 | 0.78 | TSHR (0.45) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL3816926 | 0.77 | MAOB (0.47) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL30286124 | 0.77 | TSHR (0.43) | TSHRMAOBCYP19A1ARKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233889-B1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150259306-A1 | DESAZADESFERROTHIOCIN ANALOGUES AS METAL CHELATION AGENTS | FERROKIN BIOSCIENCES INC (US) | 2015-09-17 | — | — | US | disclosed |
| US-9045440-B2 | Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents | FERROKIN BIOSCIENCES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130053387-A1 | DESAZADESFERROTHIOCIN AND DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | FerroKin BioScience, Inc. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20110275636-A1 | DESAZADESFERROTHIOCIN AND DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | FERROKIN BIOSCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-6956055-B2 | Substituted γ-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2005-10-18 | — | — | US | disclosed |
| US-4285868-A | LACTONIZATION | MOBIL OIL CORPORATION (US) | 1981-08-25 | — | — | US | disclosed |
| US-4175089-A | Preparation of gamma-butyrolactones | MOBIL OIL CORPORATION (US) | 1979-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275636-A1 | DESAZADESFERROTHIOCIN AND DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | SLC39A14, SLC40A1, FTH1 | TSHR 1908/4885MAOB 3310/4885CYP19A1 4507/4885 |
| US-20130053387-A1 | DESAZADESFERROTHIOCIN AND DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | SLC39A14, SLC40A1, FTH1 | TSHR 1908/4885MAOB 3310/4885CYP19A1 4507/4885 |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | TSHR 4793/4885MAOB 3655/4885CYP19A1 4560/4885 |
| US-20150259306-A1 | DESAZADESFERROTHIOCIN ANALOGUES AS METAL CHELATION AGENTS | SLC40A1, SLC39A14, HAMP | TSHR 1823/4885MAOB 2768/4885CYP19A1 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.